Industry Newsgene editingclinical trialscrispr therapeutics
BofA Lowers CRISPR Therapeutics Price Target
|
5.1
On January 22, 2026, BofA analyst Alec Stranahan lowered CRISPR Therapeutics' (NASDAQ:CRSP) price objective from $90 to $89 while retaining a buy rating, modestly trimming 2026 Casgevy projections. CRISPR on January 12, 2026 outlined 2026 milestones including Casgevy pediatric regulatory submissions in H1 2026, Lp(a) and CTX310 progress, Phase 2 CTX611 top-line data in H2 2026, and CTX460/CTX340 trial starts. These updates signal continued commercialization and clinical development momentum.
Scoring Rationale
Moderate industry relevance with official guidance and analyst support, limited novelty and low relevance to core AI/ML topics.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
